<?xml version='1.0' encoding='utf-8'?>
<document id="26873213"><sentence text="Systematic and comprehensive strategy for metabolite profiling in bioanalysis using software-assisted HPLC-Q-TOF: magnoflorine as an example."><entity charOffset="114-126" id="DDI-PubMed.26873213.s1.e0" text="magnoflorine" /></sentence><sentence text="Metabolite profiling plays a crucial role in drug discovery and development, and HPLC-Q-TOF has evolved into a powerful and effective high-resolution analytical tool for metabolite detection" /><sentence text=" However, traditional empirical identification is laborious and incomplete" /><sentence text=" This paper presents a systematic and comprehensive strategy for elucidating metabolite structures using software-assisted HPLC-Q-TOF that takes full advantage of data acquisition, data processing, and data mining technologies, especially for high-throughput metabolite screening" /><sentence text=" This strategy has been successfully applied in the study of magnoflorine metabolism based on our previous report of its poor bioavailability and drug-drug interactions"><entity charOffset="61-73" id="DDI-PubMed.26873213.s5.e0" text="magnoflorine" /></sentence><sentence text=" In this report, 23 metabolites of magnoflorine were tentatively identified with detailed fragmentation pathways in rat biological samples (urine, feces, plasma, and various organs) after i"><entity charOffset="35-47" id="DDI-PubMed.26873213.s6.e0" text="magnoflorine" /></sentence><sentence text="p" /><sentence text=" or i" /><sentence text="g" /><sentence text=" administration, and for most of these metabolites, the metabolic sites were determined" /><sentence text=" The phase I biotransformations of magnoflorine (M1-M7, M10-M14) consist of demethylation, dehydrogenation, hydroxylation, methylene to ketone transformation, N-ring opening, and dehydroxylation"><entity charOffset="35-47" id="DDI-PubMed.26873213.s11.e0" text="magnoflorine" /><entity charOffset="123-132" id="DDI-PubMed.26873213.s11.e1" text="methylene" /><entity charOffset="136-142" id="DDI-PubMed.26873213.s11.e2" text="ketone" /><pair ddi="false" e1="DDI-PubMed.26873213.s11.e0" e2="DDI-PubMed.26873213.s11.e0" /><pair ddi="false" e1="DDI-PubMed.26873213.s11.e0" e2="DDI-PubMed.26873213.s11.e1" /><pair ddi="false" e1="DDI-PubMed.26873213.s11.e0" e2="DDI-PubMed.26873213.s11.e2" /><pair ddi="false" e1="DDI-PubMed.26873213.s11.e1" e2="DDI-PubMed.26873213.s11.e1" /><pair ddi="false" e1="DDI-PubMed.26873213.s11.e1" e2="DDI-PubMed.26873213.s11.e2" /></sentence><sentence text=" The phase II biotransformations (M8, M9, and M15-M23) consist of methylation, acetylation, glucuronidation, and N-acetylcysteine conjugation"><entity charOffset="113-129" id="DDI-PubMed.26873213.s12.e0" text="N-acetylcysteine" /></sentence><sentence text=" The results indicate that the extensive metabolism and wide tissue distribution of magnoflorine and its metabolites may partly contribute to its poor bioavailability and drug-drug interaction, and i"><entity charOffset="84-96" id="DDI-PubMed.26873213.s13.e0" text="magnoflorine" /></sentence><sentence text="p" /><sentence text=" administration should thus be a suitable approach for isolating magnoflorine metabolites"><entity charOffset="65-77" id="DDI-PubMed.26873213.s15.e0" text="magnoflorine" /></sentence><sentence text=" In summary, this strategy could provide an efficient, rapid, and reliable method for the structural characterization of drug metabolites and may be applicable for general Q-TOF users" /><sentence text="" /></document>